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Trimetazidine and reperfusion injury
We have read with interest the editorial comment [1] on the final report of the study EMIP-FR [2] . We completely agree with Dr Tognoni on the importance of publishing the results of negative clinical studies. We also agree on the need to be extremely cautious in deriving wishful conclusions on the potential positive effects based on 'a posteriori' subset analysis, although we think that the possibility of performing such new studies cannot be rejected 'a priori'.
If additional investigations provide a sound mechanistic explanation for the selective beneficial effect of trimetazidine in patients with acute myocardial infarction not receiving thrombolytic therapy the feasibility and potential benefits of new clinical studies to test this hypothesis should be considered and weighed against the risk and costs. However, we disagree with Tognoni's extrapolations and statements regarding the clinical relevance of reperfusion injury. While the clinical importance of reperfusion injury may be debatable, it is simply a matter of logic that the negative results of a particular intervention against a particular hypothetical mechanism of reperfusion injury do not exclude the existence of the phenomenon, its clinical relevance, or the possibility of its prevention by other therapeutic interventions. This is more so because ischaemia-reperfusion leads to extremely complex and imperfectly understood biochemical derangements that can eventually lead to cell death by necrosis or apoptosis [3] [4] [5] . Among them oxygen free radicals, the mechanism hypothetically targeted by trimetazidine in the EMIP Project, could be of lesser importance [3] . The evidence that antiradical treatments may limit necrosis after transient coronary occlusion is weak and highly controversial. On the contrary, there is increasingly solid evidence that interventions set up to interfere with other pathomechanisms of cell death, like alterations of cellular cation homeosthasis leading to excessive contractile activation and hypercontracture, can effectively limit myocardial cell death when applied at the time of reperfusion [3, 6] . The main contribution of the EMIP Project to the issue of the clinical relevance of reperfusion injury could remind us that the era during which reperfusion injury was synonymous with oxygen free radical injury is well over. [1] together with an Editorial discussing the results in the light of the rationale of the study [2] . However, as viewed by a basic scientist not involved in clinical concerns, an important angle of this debate remained unexplored in these two papers. The clinical trial included nearly 20 000 patients in the acute phase of myocardial infarction to investigate the effect of trimetazidine with and without interventional thrombolysis. The rationale for this study was based on numerous pharmacological data suggesting the efficiency of trimetazidine in reducing the effects of oxidative stress, both in vivo and in vitro, which would confer to the molecule a beneficial effect in reperfusion injury. On this basis, the study was clearly built to demonstrate a positive effect of short-term trimetazidine treatment (48 h) in the thrombolyzed stratum, considered as a prompt to reperfusion injury, and no effect of the drug in the nonthrombolyzed stratum. The results of the study pointed out, as outlined in the editorial, that trimetazidine 'does not provide any clinical advantage over placebo in patients exposed to the risk of reperfusion injury' [2] . Conversely, the authors of the EMIP-FR study reported a significant beneficial effect of the drug in the nonthrombolyzed stratum. The editorial points out that the results contradict the trial hypothesis, and suggests that the claim for the use of trimetazidine (or any molecule with the same pharmacological rationale) in nonthrombolyzed patients cannot be justified from this trial [2] . The editorial concludes that the EMIP-FR trial addresses the question of the clinical relevance of reperfusion injury.
Large scale trials like EMIP-FR involving 20 000 patients, 393 centres in 15 countries, hundreds of investigators, and a huge amount of money need several years from the conception of the rationale to the publication of the results. During this time, the research continues and, from a pharmacological point of view, it appears necessary to revisit the EMIP-FR story to follow the progress of this concept during the 1993-2000 period, running from decision to publication of the EMIP-FR project.
The data that served as a basis for the EMIP-FR study, reported a positive effect of trimetazidine in oxidative stress in vitro. Since no free-radical scavenger property could be demonstrated, the mechanism was considered either able to correct the situation promptly to generate free radicals, or as a protective effect against the free radicals' deleterious effects.
However, the question of considering this point as either a cause or a consequence of the trimetazidine effect was raised when the efficiency of the drug was demonstrated in the absence of oxidative stress in isolated heart and ventricular myocyte models [3, 4] . This antiischaemic effect of the drug at the cellular level was associated with both a prevention of hypoxia-induced electro-mechanical alterations and a decreased ability to produce energy from fatty acids [5] . Such a decreased fatty acid utilization, which induces increased glucose utilization, leads to a decrease in oxygen requirement [6] and this sequence appears as an exciting strategy in the pharmacology of cardiac ischaemia, provided the accumulation of the non-oxidized fatty acids could be prevented. Several experimental studies have shown that trimetazidine may fulfil these requirements: (i) because the drug was shown to inhibit beta-oxidation [7] and (ii) because it was demonstrated to increase the turnover of membrane phospholipid [8] redirecting the fatty acids towards membrane structures [9] . Incidentally, the decreased betaoxidation associated with enhanced membrane homeostasis could, in turn, contribute to increase cell resistance to oxidative stress. This view of the mechanism of action of an antiischaemic drug devoid of haemodynamic effect fits the new concept of 'metabolic effector', a drug displaying a significant efficacy in the cytoprotection of ventricular myocytes. In the last few years, trimetazidine was reported to improve the exercise test scores in patients with angina pectoris and several positive results were obtained in short-term clinical trials in situations known for a high metabolic implication, either as monotherapy or as associated therapy with calcium inhibitors or beta-blockers [10, 11] , associations regarded as efficient due to the non-overlapping mechanisms.
Considering these data, the EMIP-FR investigation can be regarded and discussed for both negative and positive results. In the thrombolyzed stratum, the data justify the observation that trimetazidine does not provide any clinical advantage in patients exposed to the risk of reperfusion injury. But the new insights in the mechanism support the explanation proposed by the authors that the impossibility of any pre-treatment might explain this lack of effect. First, because the effect of trimetazidine in oxidative stress is a consequence of its metabolic effect, which should thus occur first, and anyway before the reperfusion injury. Second, because the plasma condition at thrombolysis (high free fatty acid content resulting from stress and fasting associated with rapid reoxygenation) may provide an abrupt return to a detrimental use of fatty acids. These conditions may not be ideal to reveal a trimetazidineinduced increase of the glucose/fatty acid balance, which could, by contrast, be more readily evidenced under GIK treatment. This view supports the regrets by the authors who had to exclude from the study the patients already treated with trimetazidine. In contrast, in the non-thrombolyzed stratum, the per-protocol analysis revealed a significant effect of the drug in reducing 35-day mortality, hospital mortality, cardiovascular mortality, and combined end-point, and some other outcomes in the intention-totreat population [1] . In this case, there was no abrupt return to high fatty acid and oxygen supply. The heart cell conditions are traditional to ischaemia, and were closer to the metabolic conditions observed in angina pectoris. Thus, the positive clinical results of trimetazidine fit the metabolic cytoprotection, in spite of the very short treatment duration. Trimetazidine did allow a cytoprotection of cardiac myocytes in the acute phase of MI in the non-thrombolyzed patients, which resulted in positive clinical outcomes.
We can now return to the editorial suggesting that the use of trimetazidine (or other molecules with the same pharmacological rationale) in nonthrombolyzed patients cannot be justified from this trial. If trimetazidine is viewed as a rationale based on antioxidative properties (as the other related molecules), as in the main paper and the editorial, we cannot disagree with this conclusion. Conversely, if trimetazidine is viewed, according to recent insights, as a rationale base on metabolic cytoprotection (and ranolazine appears to be the only related molecule), the results of EMIP-FR appear as very positive and could favourably support the discussion on the use of metabolic effectors in cardiac pathology.
Indeed, the EMIP-FR study provided interesting results for the scientific community involved in new concepts in cardiac pharmacology. This trial showed that a metabolic effector devoid of haemodynamic activity could give significant beneficial results in the acute phase of MI.
To our knowledge, after numerous pre-clinical experimental arguments, this is one of the first large scale demonstrations to show that specific treatment of the cardiac myocyte may lead to positive outcomes in MI patients. The heart is both a pump and a furnace. After investigating the treatment of the pump for decades, we are just starting to treat the furnace. [1] , as well as the accompanying editorial by Dr Giani Tognoni [2] . The paper by the EMIP-PR Group investigated whether 48 h i.v. use of trimetazidine alters the short-and long-term outcome of patients with an acute myocardial infarction. The results of this large prospective multicentred trial demonstrate that trimetazidine reduces mortality in nonthrombolyzed patients, but not in the thrombolyzed patients. This study was criticized in the Tognoni editorial due, in part, to a rationalization that the supposed free radical antagonizing effects of trimetazidine are not consistent with a lack of benefit of trimetazidine in the thrombolyzed group. Presumably inhibition of free radical production should be most beneficial under conditions of reperfusion (i.e. thrombolysis) where free radical production is greatest (i.e. reperfusion injury). It is clear that Dr Tognoni is not a strong proponent of the concept of 'reperfusion injury' and points out the disappointing clinical experience with free radical modification in the setting of reperfusion following an acute myocardial infarction. While I do not disagree with Dr Tognoni on this point, I would like to point out that it is unlikely that the mechanism of action of trimetazidine is related to an inhibition of free radical production.
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Trimetazidine is an effective antiischaemic agent which acts independent of haemodynamic effects (see [3] for review). Until recently, the mechanism of action of trimetazidine was not understood, although it was clear it had direct cytoprotective effects on the heart [3] . While early studies suggested that trimetazidine may protect the heart against free radical-induced membrane damage [4] , it is unlikely that this can explain the antiischaemic properties of trimetazidine at clinically relevant concentrations. Recent studies have demonstrated that the beneficial effects of trimetazidine can be explained by an optimization of energy metabolism in the heart. We have shown that trimetazidine acts by inhibition of myocardial fatty acid oxidation, secondary to inhibition of long chain 3-ketoacyl CoA thiolase [5] . This results in an increase in glucose oxidation, resulting in an improved coupling between glycolysis and glucose oxidation. This decreases proton production from uncoupled glucose metabolism, resulting in a decrease in intracellular acidosis, and a decrease in intracellular Na+ accumulation [6] . These effects of trimetazidine on myocardial energy metabolism have the potential to markedly improve cardiac efficiency both during the following ischaemia (see [7] for review). The EMIP-FR group originally began their clinical study, which examined the effects of trimetazidine on the outcome of patients with acute myocardial infarction, assuming that trimetazidine acts by inhibiting free radical production. Indeed, the acronym 'EMIP-FR' stands for 'European Myocardial Infarction Project-Free Radicals'. Unfortunately, the EMIP-FR Group paper does not cite recent studies demonstrating that trimetazidine is unlikely to act as an inhibitor of free radical production, but rather acts as a 'metabolic modulator' that optimizes energy metabolism in the heart. I believe this omission led Dr Tognoni to assume in his editorial that the lack of benefit of trimetazidine in thrombolyzed patients was inconsistent with trimetazidine acting as an inhibitor of free radical production.
The benefits observed with trimetazidine in non-thrombolyzed AMI patients is consistent with the actions of trimetazidine acting as a 'metabolic modulator'. Previous studies in AMI patients have shown that metabolic therapy with glucose-insulinpotassium (GIK) can benefit patients in the absence of thrombolysis (see [8] for review of clinical trials). Furthermore, the mechanism of action of trimetazidine is consistent with trimetazidine having a beneficial effect on jeoparidized ischaemic myocardium in the absence of reperfusion [7] . While Dr Tognoni also points out other deficiencies in the EMIP-FR Group study related to subanalysis procedures, I do not agree with Dr Tognoni that the results of the EMIP-FR study demonstrate the lack of biological relevance of free radical scavenging approach to treating AMI.
Since trimetazidine does not act as an inhibitor of free radical production, this question is still unresolved. However, the promising results showing trimetazidine decreases mortality in non-thrombolyzed AMI patients, combined with recent success of 'metabolic modulation' using GIK in AMI patients [9] , suggests that the concept of optimizing energy metabolism in the heart warrants further investigation as a clinical approach to treating patients with AMI. 
